Hepatobiliary pancreatic tumor
Conditions
Interventions
Postoperative immunotherapy combined with tyrosine kinase inhibitor to prevent recurrence of hepatobiliary and pancreatic tumors:None
Sponsors
Second Affiliated Hospital of Harbin Medical University
Eligibility
Sex/Gender
All
Age
43 Years to 74 Years
Inclusion criteria
Inclusion criteria: Patients with hepatobiliary and pancreatic tumors who underwent radical tumor resection and postoperative immunotherapy combined with receptor tyrosine kinase inhibitor to prevent tumor recurrence from 2020.12.22.
Exclusion criteria
Exclusion criteria: Those whose sample size could not meet the sequencing requirements, those who lost the interview, and those who did not follow the doctor's advice to use immunotherapy combined with receptor tyrosine kinase inhibitor to prevent tumor recurrence after surgery were excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival time;Recurrence status;Sequencing data;Metabolite sequencing data; | — |
Secondary
| Measure | Time frame |
|---|---|
| Tumor diameter;Barcelona stage of tumor;Age;Gender; | — |
Countries
China
Contacts
Public ContactYunfu Cui
Second Affiliated Hospital of Harbin Medical University
Outcome results
None listed